Back

The potential impact of reductions in international donor funding on tuberculosis in low- and middle-income countries

Clark, R. A.; McQuaid, C. F.; Richards, A. S.; Bakker, R.; Sumner, T.; Prys-Jones, T. O.; Houben, R. M. G. J.; White, R. G.; Horton, K. C.

2025-04-25 public and global health
10.1101/2025.04.23.25326313 medRxiv
Show abstract

BackgroundTuberculosis services in many settings rely heavily on international donor funding. In 2025, the United States Agency for International Development (USAID) was dismantled, and other countries also announced cuts to overseas development assistance. We quantified potential epidemiological impacts attributable to these reductions in international donor funding. MethodsWe calibrated a deterministic tuberculosis model to epidemiological indicators in low- and middle-income countries. We projected three future scenarios assuming: a) levels of funding in 2024 continue through 2035, b) termination of USAID funding from 2025, and c) additional reductions in funding through The Global Fund in line with current donor announcements from 2025. We assumed a reduction in tuberculosis treatment initiation rates proportional to budget reductions for each scenario, estimating cumulative excess incident episodes of symptomatic tuberculosis and tuberculosis deaths. FindingsWe modelled 79 countries, representing 91% of global tuberculosis incidence and 90% of global tuberculosis mortality in 2023. Our modelling suggested that the termination of USAID funding may lead to 420 500 excess tuberculosis deaths by 2035. Further reductions in funding in line with current announcements by the United States, France, the United Kingdom, and Germany may lead to an additional 699 200, 63 100, 50 500, and 30 500 TB deaths, respectively. Impacts would be greatest in low-income countries. InterpretationWe estimate substantial potential impacts on tuberculosis morbidity and mortality due to reductions in international donor funding. Expanded support from domestic and international donors is essential to address immediate gaps in prevention, diagnosis, and treatment. FundingThis work was unfunded.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
The Lancet Global Health
24 papers in training set
Top 0.1%
32.2%
2
BMJ Global Health
98 papers in training set
Top 0.4%
8.2%
3
PLOS Medicine
98 papers in training set
Top 0.5%
6.2%
4
The Journal of Infectious Diseases
182 papers in training set
Top 0.5%
6.2%
50% of probability mass above
5
Clinical Infectious Diseases
231 papers in training set
Top 1%
4.2%
6
PLOS Global Public Health
293 papers in training set
Top 2%
3.5%
7
Nature Communications
4913 papers in training set
Top 44%
2.7%
8
PLOS ONE
4510 papers in training set
Top 44%
2.7%
9
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 2%
2.0%
10
BMC Public Health
147 papers in training set
Top 3%
1.8%
11
The Lancet
16 papers in training set
Top 0.2%
1.8%
12
Emerging Infectious Diseases
103 papers in training set
Top 1%
1.8%
13
Vaccine
189 papers in training set
Top 1%
1.6%
14
Thorax
32 papers in training set
Top 0.5%
1.6%
15
The Lancet Infectious Diseases
71 papers in training set
Top 2%
1.5%
16
International Journal of Epidemiology
74 papers in training set
Top 2%
1.5%
17
BMC Infectious Diseases
118 papers in training set
Top 3%
1.5%
18
The Lancet Public Health
20 papers in training set
Top 0.4%
1.3%
19
BMC Medicine
163 papers in training set
Top 5%
1.2%
20
Epidemiology and Infection
84 papers in training set
Top 2%
1.2%
21
eClinicalMedicine
55 papers in training set
Top 1%
0.9%
22
BMJ Open
554 papers in training set
Top 11%
0.9%
23
The Lancet Microbe
43 papers in training set
Top 1%
0.8%
24
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 45%
0.7%
25
The Lancet Digital Health
25 papers in training set
Top 1%
0.7%
26
Transactions of The Royal Society of Tropical Medicine and Hygiene
16 papers in training set
Top 0.7%
0.7%
27
Pediatrics
10 papers in training set
Top 0.3%
0.7%